You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB
SBC: CELLF-BIO, LLC Topic: 300Project Summary AbstractFecal incontinenceFIthe involuntary soiling of various amounts of liquid and solid stoolis often devastating from a socialpsychologicaland hygiene perspectiveMen and women suffer from FI equally with a range ofin people agedyearsThe prevalence increases to overin people older thanyearsFI may result from an isolated or combined loss of smooth muscle functionIASskeletal muscl ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Device for rapid extraction of rare pathogens from raw samples
SBC: Redbud Labs, Inc. Topic: RABSTRACTRedbud Labs proposes to develop a low costintegrated microfluidic system to purify and concentrate pathogens directly frommL of whole bloodwith the goal of improving the sensitivity of downstream blood culture and molecular diagnostic assays used in sepsis diagnosis and treatmentPhase I studies have demonstrated that our technologybased on actuated surface attached postsASAPscan achieve hi ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Accelerated discovery of methylation targeted therapeutic development
SBC: Epicypher, Inc. Topic: 102PROJECT SUMMARYNucleosomesNucsare the repeating units of chromatinmade up of DNA wrapped around a histone octamerChanges in chromatin structurefunction can dramatically impact downstream gene expression and cellular physiologydriving oncogenic reprogramming and cancer progressionThis epigenetic regulation of chromatin is controlled by two major modificationshistone post translational modifications ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a first-in-class therapeutic for producing 'on-demand' voiding
SBC: Dignify Therapeutics LLC Topic: 400PROJECT SUMMARYABSTRACTAging and diabetesas well as many neurological conditionssuch as multiple sclerosisParkinsonandapos s diseasespina bifidastrokeand spinal cord injurySCIcan result in loss of voluntary voiding of urine and require intermittent bladder catheterization for voidingCatheter use is associated with increased incidence of health problemspredominately repeated urinary tract infection ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeting leukocyte metabolism to treat human autoimmune disease
SBC: Immunext, Inc. Topic: RImmuNext has defined an anti MCTmonoclonal antibodymAbthat will be developed for the treatment of human autoimmune diseaseThe membrane monocarboxylate nutrient transporter SLCAMCTis a multi pass transmembrane protein responsible for the facilitated transport of critical metabolitesincluding products of glycolysislactatepyruvate and ketonesOur strong preliminary data support the tenet that mAbs tha ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Detecting breast cancer with a simple blood test using an accessible and low-cost novel real-time platform
SBC: Inanovate, Inc. Topic: 102Project SummaryAlthough widespread screening by mammography has successfully cut mortality from breast cancerBCathe exquisite sensitivity of the technique results in a startling number offalse positivesOf approximatelymillion women who receive a positive mammogram each yearfewer thanwill be diagnosed with BCaCumulativelythe economic cost of followup diagnostics to resolve falsepositive mammograms ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A novel protein engineering tool for rapid manufacturing of designer nucleosomes
SBC: Epicypher, Inc. Topic: 103PROJECT SUMMARYEpiCypher is pioneering the commercial development of fully defined recombinantsemi synthetic nucleosomes carrying specific histone post translational modificationsPTMstermed designer nucleosomes or dNucsTMfor epigenetics researchWe currently use native chemical ligationNCLto generate modified histones for dNuc assemblyand have developed proprietary methods to efficiently manufactur ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Lung Cancer
SBC: CivaTech Oncology, Inc. Topic: 102CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumorsThe Company has developed a novelpolymer encapsulatedmembrane like radiation source that emits radiation on only one side of the devicethe CivaSheetThis directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combined cancer t ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
SBC: Advanced Chemotherapy Technologies, Inc. Topic: 102PROJECT SUMMARY Advanced Chemotherapy TechnologiesACThas developed a proprietary implantable iontophoretic device that facilitates the infusion of chemotherapy agents directly into a cancer tumorminimizing toxic exposure to the vascular system and other organsACT is focusing specifically on treating pancreatic cancer with gemcitabine for this proposalPancreatic cancer has a five year survival rate ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health